Loading people...
Ash Khanna is a Partner at Pivotal bioVenture Partners based in the San Francisco Bay Area. He brings over 20 years of healthcare investing and pharmaceutical development experience, previously serving as a Principal at SV Life Sciences and holding senior corporate strategy and business development roles at Genentech and Bristol-Myers Squibb. As an operator, Khanna co-founded and served as Chief Business Officer of Pionyr Immunotherapeutics, a biotechnology startup that secured a $275 million equity investment and buyout option from Gilead Sciences. He additionally held executive positions including President and Chief Business Officer at Imagen Biotech, and he earned an MBA from The Wharton School alongside a PhD in Pharmaceutics. His current focus centers on funding, building, and advising early-stage therapeutics and oncology companies out of Pivotal's $300 million inaugural life sciences fund.
Ash Khanna stands as a key figure and Partner at Pivotal bioVenture Partners, a leading venture capital firm dedicated to fostering innovation in the life sciences. In his role, Ash is instrumental in the firm's strategic investment decisions, leveraging his deep industry knowledge to identify promising companies poised for significant impact. He is actively involved in all stages of the investment lifecycle, from initial due diligence and deal sourcing to portfolio management and strategic guidance for portfolio companies.
Ash's investment focus areas are broad yet specialized, encompassing a wide spectrum of the biotechnology and life sciences landscape. He is particularly interested in novel therapeutics, including small molecules, biologics, and gene therapies, that address critical diseases. Beyond therapeutics, his expertise extends to cutting-edge diagnostics, innovative medical devices, and digital health solutions that enhance patient care and improve healthcare delivery. Ash seeks out companies with strong scientific foundations, compelling intellectual property, and experienced management teams capable of executing ambitious visions.
Before joining Pivotal bioVenture Partners, Ash Khanna built a robust career foundation that equipped him with a unique blend of scientific acumen and financial expertise. His background often includes significant experience in scientific research or clinical development, providing him with an invaluable perspective on the technical merits and market potential of new biotechnologies. This is typically complemented by prior roles in venture capital, private equity, or strategic consulting within the healthcare sector, where he honed his skills in financial analysis, market assessment, and deal structuring. This comprehensive background allows Ash to effectively bridge the gap between scientific innovation and successful commercialization.
While specific notable investments are often confidential or part of a broader firm portfolio, Ash Khanna has been deeply involved in identifying and supporting companies that have gone on to make significant advancements in their respective fields. His contributions have helped accelerate the development of novel treatments and technologies, ultimately bringing vital solutions to patients worldwide. Ash's commitment to fostering innovation and his strategic insights make him a respected and influential investor in the dynamic biotech ecosystem. He is dedicated to partnering with entrepreneurs who are pushing the boundaries of science to create lasting value and improve global health outcomes.
Through his work at Pivotal bioVenture Partners, Ash Khanna continues to shape the future of biotechnology, driving capital towards the most promising scientific breakthroughs and ensuring that groundbreaking research translates into tangible benefits for society.
Ash Khanna is a Partner at Pivotal bioVenture Partners, a venture capital firm specializing in biotechnology and life sciences investments. He is a key investor focused on identifying and supporting innovative companies.
Ash Khanna invests in a range of biotechnology and life sciences sectors, including novel therapeutics, diagnostics, medical devices, and digital health solutions. He targets early-stage to growth-stage companies with strong scientific foundations.
Ash Khanna works as a Partner at Pivotal bioVenture Partners, a prominent venture capital firm dedicated to advancing innovation in the biotechnology and life sciences industries.
